Therapy Areas: Inflammatory Diseases
SciBase technology selected as primary endpoint in NIH-led skin exposure study
15 October 2026 - Swedish medical technology company SciBase Holding AB (STO: SCIB), which develops AI-based dermatology assessment devices, said on Thursday it will participate in a new study led by ...
argenx reports positive Phase 2 results for FB102 in coeliac disease
8 October 2026 - European immunology company argenx SE (EBR & NASDAQ: ARGX) on Thursday reported positive top-line results from a Phase 2 study of FB102, a first-in-class CD122 inhibitor, in adult...
Boehringer Ingelheim announces availability of new Quarterable Snap-Tab design for PREVICOX (firocoxib) Chewable Tablets
8 October 2026 - Pharmaceutical company Boehringer Ingelheim announced on Wednesday the availability of the new Quarterable Snap-Tab design for PREVICOX (firocoxib) Chewable Tablets for dogs, followin...
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
6 October 2026 - Mozart Therapeutics Inc, a developer of CD8 Treg network modulators for the treatment of autoimmune disease, announced on Monday the presentation of clinical and preclinical data for ...
CSL and Alentis partner for lixudebart development and commercialisation for rare kidney and liver diseases
5 October 2026 - Australian biopharma company CSL Limited (ASX:CSL) (USOTC:CSLLY) and Swiss biotechnology company Alentis Therapeutics announced on Sunday that they have entered into an exclusive glob...
Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
2 October 2026 - US healthcare company Johnson & Johnson (NYSE: JNJ) on Friday announced the release of two-year Phase 3 results from ICONIC-TOTAL assessing ICOTYDE (icotrokinra) in adults and ado...